Imdur (Isosorbide Mononitrate)

Isosorbide mononitrate is converted in the body to nitric oxide, a potent vasodilator. Nitric oxide activates guanylate cyclase, raising cyclic GMP levels in vascular smooth muscle, which relaxes the vessels, lowers cardiac preload and afterload, and consequently decreases the heart’s oxygen demand.

The dosage of Imdur is individualized by the prescribing clinician based on the patient’s clinical condition, response, and tolerance. Healthcare professionals determine the appropriate strength, frequency, and any titration schedule required for optimal therapeutic effect.

The safety of isosorbide mononitrate in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Imdur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Imdur belongs to the nitrate class, offering sustained nitric‑oxide release, whereas other anti‑anginals such as beta‑blockers or calcium‑channel blockers act through different mechanisms like heart‑rate reduction or calcium influx inhibition. Nitrates are particularly effective for patients needing vasodilation to relieve chest pain.

Imdur should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Maintaining these conditions helps preserve tablet integrity and potency throughout its shelf life.

Imdur is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing and any specific administration guidelines.

The most serious risks include severe hypotension, syncope, life‑threatening arrhythmias, and rare allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, or signs of a severe allergic response.

Imdur is contraindicated in patients with known hypersensitivity to isosorbide mononitrate or other nitrates, those who have taken phosphodiesterase‑5 inhibitors within 24 hours, and individuals with severe anemia, closed‑angle glaucoma, or uncontrolled hypotension.